Brief: Shield Therapeutics Reports 2025 Group Net Revenues & Other Income At $49.7 Million
09/04/2026 12:43
April 9 (Reuters) - Shield Therapeutics PLC STXS.L: SHIELD THERAPEUTICS PLC - 2025 GROUP NET REVENUES AND OTHER INCOME $49.7 MILLION; ACCRUFER NET REVENUES UP 56% TO $45.8 MILLION SHIELD THERAPEUTICS PLC - 2025 LOSS FOR THE YEAR REDUCED TO $17.7 MILLION FROM $27.2 MILLION SHIELD THERAPEUTICS PLC: CO. EXPECTS TO DELIVER AN OPERATING PROFIT IN 2026 Source text: ID:nRSI8611Za Further company coverage: STXS.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update